Trandolapril | CAS#87679-37-6

Trandolapril
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318894

CAS#: 87679-37-6

Description: Trandolapril is an ACE inhibitor used to treat high blood pressure. It acts by competitive inhibition of angiotensin converting enzyme (ACE), a key enzyme in the renin-angiotensin system which plays an important role in regulating blood pressure..

Chemical Structure

Trandolapril

CAS# 87679-37-6

Instruction

Theoretical Analysis

MedKoo Cat#: 318894
Name: Trandolapril
CAS#: 87679-37-6
Chemical Formula: C24H34N2O5
Exact Mass: 430.25
Molecular Weight: 430.537
Elemental Analysis: C, 66.95; H, 7.96; N, 6.51; O, 18.58

Price and Availability

Size	Price	Availability
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
200mg	USD 1250	2 Weeks
500mg	USD 1950	2 Weeks
1g	USD 2650	2 Weeks
2g	USD 4950	2 Weeks
5g	USD 6950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Trandolapril, Mavik, Gopten, Odrik, RU 44570

IUPAC/Chemical Name: (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid

InChi Key: VXFJYXUZANRPDJ-WTNASJBWSA-N

InChi Code: InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

SMILES Code: O=C([C@H]1N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)[C@@]3([H])CCCC[C@]3([H])C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: DMF: 15 mg/ml; DMSO: 25 mg/ml; Ethanol: 0.25 mg/ml; PBS (pH 7.2): 1 mg/ml.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 430.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Cohen V, Jellinek SP, Fancher L, Sangwan G, Wakslak M, Marquart E, Farahani C. Tarka® (trandolapril/verapamil hydrochloride extended-release) overdose. J Emerg Med. 2011 Mar;40(3):291-5. doi: 10.1016/j.jemermed.2008.10.015. Epub 2009 Feb 26. Review. PubMed PMID: 19249183.

2: Diaz A, Ducharme A. Update on the use of trandolapril in the management of cardiovascular disorders. Vasc Health Risk Manag. 2008;4(6):1147-58. Review. PubMed PMID: 19337528; PubMed Central PMCID: PMC2663436.

3: Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. Vasc Health Risk Manag. 2007;3(4):453-65. Review. PubMed PMID: 17969376; PubMed Central PMCID: PMC2291330.

4: Muijsers RB, Curran MP, Perry CM. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Drugs. 2002;62(17):2539-67. Review. PubMed PMID: 12421112.

5: Widimský J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother. 2000 Mar;1(3):515-35. Review. PubMed PMID: 11249535.

6: Buksa M. [Trandolapril in the prevention of the sequelae of left ventricular systolic dysfunction after acute myocardial infarct]. Med Arh. 2000;54(2):103-6. Review. Croatian. PubMed PMID: 10934839.

7: Ottesen MM, Jørgensen S, Kjøller E, Videbaek J, Køber L, Torp-Pedersen C. Age-distribution, risk factors and mortality in smokers and non-smokers with acute myocardial infarction: a review. TRACE study group. Danish Trandolapril Cardiac Evaluation. J Cardiovasc Risk. 1999 Oct;6(5):307-9. Review. PubMed PMID: 10534133.

8: Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O. Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). J Hypertens Suppl. 1997 Mar;15(2):S119-22. Review. PubMed PMID: 9218208.

9: Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hypertens. 1995 Oct;8(10 Pt 2):63S-67S. Review. PubMed PMID: 8845086.

10: Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994 Jul;48(1):71-90. Review. PubMed PMID: 7525196.

11: Gaillard CA, de Leeuw PW. Clinical experiences with trandolapril. Am Heart J. 1993 May;125(5 Pt 2):1542-6. Review. PubMed PMID: 8480627.

12: García Donaire JA, Ruilope LM. Trandolapril/verapamil combination in hypertensive diabetic patients. Vasc Health Risk Manag. 2007;3(1):77-82. Review. PubMed PMID: 17583177; PubMed Central PMCID: PMC1994049.

13: Reynolds NA, Wagstaff AJ, Keam SJ. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs. 2005;65(13):1893-914. Review. PubMed PMID: 16114984.

14: Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. Review. PubMed PMID: 12852701.

15: Coca A, Rabasseda X. Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study. Drugs Today (Barc). 2003 Jan;39(1):5-18. Review. PubMed PMID: 12669106.

16: Peters DC, Noble S, Plosker GL. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56(5):871-93. Review. PubMed PMID: 9829159.

17: Dooley M, Goa KL. Fixed combination verapamil SR/trandolapril. Drugs. 1998 Nov;56(5):837-44; discussion 845-6. Review. PubMed PMID: 9829157.

18: Hansen JF. Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. J Hypertens Suppl. 1998 Jan;16(1):S71-4. Review. PubMed PMID: 9534101.

19: Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl. 1997 Mar;15(2):S51-3. Review. PubMed PMID: 9218199.

20: Kirchengast M. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. J Hypertens Suppl. 1997 Mar;15(2):S27-33. Review. PubMed PMID: 9218195.

Your view history

Trandolapril featured